Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.45 |
| ▸ | ATR | Q13535 | 3/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044297 | 0.89 | MAPKAPK5 (0.41) | TTBK1TTBK2EPHB4MAPKAPK5PIK3CD | |
| SCHEMBL2199371 | 0.86 | TTBK1 (0.47) | TTBK1TTBK2EPHB4MAPKAPK5ATR | |
| SCHEMBL12618583 | 0.84 | ATR (0.53) | TTBK1TTBK2EPHB4MAPKAPK5ATR | |
| SCHEMBL1044940 | 0.80 | JAK2 (0.51) | TTBK1TTBK2MAPKAPK5PIK3CAPIK3CG | |
| SCHEMBL1043468 | 0.80 | JAK2 (0.59) | TTBK1TTBK2MAPKAPK5PIK3CAZAP70 | |
| SCHEMBL1399517 | 0.78 | JAK2 (0.38) | EPHB4MAPKAPK5ATRPIK3CDPIK3CA | |
| SCHEMBL1044285 | 0.77 | MAPKAPK5 (0.48) | TTBK1TTBK2MAPKAPK5ZAP70JAK2 | |
| SCHEMBL1045483 | 0.76 | MAPKAPK5 (0.52) | TTBK1TTBK2MAPKAPK5JAK2 | |
| SCHEMBL10134404 | 0.74 | MAPKAPK5 (0.41) | EPHB4MAPKAPK5ATRPIK3CAMTOR | |
| SCHEMBL1046703 | 0.74 | MAPKAPK5 (0.75) | TTBK1TTBK2MAPKAPK5JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | claimed |
| EP-2086540-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-08-12 | — | — | EP | claimed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | claimed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | claimed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | TTBK1 346/4885TTBK2 525/4885EPHB4 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.